Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Trastuzumab deruxtecan for unresectable or metastatic non-small-cell lung cancer whose tumours have activating HER2 (ERBB2) mutations and who have received a prior systemic therapy

Condition

Cancer

Respiratory

6 February 2026

-

Published on 06 Feb 2026
Last Updated on 06 Feb 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended trastuzumab deruxtecan (T-DXd) for inclusion on the MOH List of Subsidised Drugs for treating patients with unresectable or metastatic non-small-cell lung cancer whose tumours have activating human epidermal growth receptor 2 (HER2) mutations and who have received a prior systemic therapy. The decision was based on the uncertainties in the clinical and cost effectiveness of T-DXd in the patient population, and an unacceptable pricing proposal by the company.

Clinical indication, subsidy class and MediShield Life claim limit for T-DXd are provided in the Annex.

Guidance_Trastuzumab deruxtecan for unresectable or metastatic non-small-cell lung cancer whose tumours have activating HER2 (ERBB2) mutations and who have received a prior systemic therapy (6 Feb 2026) (opens in new tab)